A5025873791- Hormonal and reproductive studies
- Bladder and Urothelial Cancer Treatments
- Sexual function and dysfunction studies
- Sexual Differentiation and Disorders
- Urinary Bladder and Prostate Research
- Urinary and Genital Oncology Studies
- Pharmacology and Obesity Treatment
- Prostate Cancer Treatment and Research
- Sexuality, Behavior, and Technology
- Muscle metabolism and nutrition
- Urological Disorders and Treatments
- Urinary Tract Infections Management
- Cancer Research and Treatments
- Epigenetics and DNA Methylation
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Pharmacological Effects and Assays
- Genital Health and Disease
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
- Immune responses and vaccinations
- Hypothalamic control of reproductive hormones
- Sleep and Wakefulness Research
- Medical Imaging and Pathology Studies
- Urologic and reproductive health conditions
Hospital Militar Central
2025
Marquette University
2025
Saint Peter's University Hospital
2024
Queen's University
2012-2022
Hospital del Salvador
2022
Universidad de Costa Rica
2017
Amherst College
2013-2016
Kingston General Hospital
2000-2013
Memorial Sloan Kettering Cancer Center
2004-2007
Johns Hopkins University
2004
No AccessJournal of Urology1 Aug 1976Intracavitary Bacillus Calmette-guerin in the Treatment Superficial Bladder Tumors A. Morales, D. Eidinger, and A.W. Bruce MoralesA. Morales Current address: Laboratory Immunodiagnosis, Building 8, Room 118, National Institutes Health, Bethesda, Maryland, 20014. More articles by this author , EidingerD. Eidinger BruceA.W. View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)58737-6AboutPDF ToolsAdd to favoritesDownload CitationsTrack...
Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern recurrence in 9 patients has altered favorably. Although the findings are still preliminary they appear to hold promise a new therapeutic approach treatment group neoplasms for which effective therapy is lacking.
Demographic data clearly demonstrate that the percentage of population in older age group is increasing. Androgen deficiency aging male has become a topic increasing interest and debate throughout world. Cross-sectional longitudinal indicate testosterone falls progressively with significant men over 60 years have serum levels are below lower limits young adult (age 20–30 years) (1–4). The principal questions raised by these observations whether hypogonadal will benefit from treatment what be...
No AccessJournal of Urology1 Mar 1992Incidence and Treatment Complications Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer Donald L. Lamm, Ad P.M. Van Der Meijden, Alvaro Morales, Stanley A. Brosman, William J. Catalona, Harry W. Herr, Mark S. Soloway, Adolphe Steg, Frans M.J. Debruyne LammDonald Lamm More articles by this author , MeijdenAd Meijden MoralesAlvaro Morales BrosmanStanley Brosman CatalonaWilliam Catalona HerrHarry Herr SolowayMark Soloway StegAdolphe...
Demographic data clearly demonstrate that the percentage of population in older age group is increasing. Androgen deficiency aging male has become a topic increasing interest and debate throughout world. Cross-sectional longitudinal indicate testosterone falls progressively with significant men over 60 years have serum levels are below lower limits young adult (age, 20–30 years) (Gray et al, 1991; Harman 2001; Araujo 2007; Wu 2008). The principal questions raised by these observations...
We review how the bacillus Calmette-Guerin vaccine evolved to become standard therapy for superficial bladder cancer.We reviewed historical literature describing origin of as an anticancer agent and its singular success most effective immunotherapy used against a human neoplasm.The association between tuberculosis cancer, demonstration that invoked immunological reactivity, inhibiting tumor growth in experimental animal models, led clinical trials showing intravesical eradicated prevented...
We compared hexaminolevulinate fluorescence cystoscopy with white light for detecting Ta and T1 papillary lesions in patients bladder cancer.A total of 311 known or suspected cancer underwent instillation 50 ml 8 mM HAL 1 hour. The was inspected using cystoscopy, followed by blue (fluorescence) cystoscopy. Papillary were mapped resected histological examination.Noninvasive pTa tumors found 108 196 evaluable (55.1%). In 31 (29%) at least more tumor detected than (p<0.05). Six these had no...
Most trials of immunomodulators in metastatic renal-cell carcinoma have been uncontrolled and subject to selection bias. The objective this blinded, placebo-controlled study was compare overall response rates, time disease progression, survival patients with treated recombinant human interferon gamma-1b or placebo.
Click to increase image sizeClick decrease sizeAGING HYPOGONADISM TESTOSTERONE REPLACEMENT
Demographic data clearly demonstrate that the per cent of population in older age group is increasing. Androgen deficiency ageing male has become a topic increasing interest and debate throughout world. Cross-sectional longitudinal indicate testosterone falls progressively with significant men over 60 years have serum levels are below lower limits young adult (age 20–30 years) (Gray et al., 1991; Harman 2001; Araujo 2007; Wu 2008). The principal questions raised by these observations whether...
No AccessJournal of UrologyClinical Urology: Original Article1 Mar 1997Testosterone Supplementation for Hypogonadal Impotence: Assessment Biochemical Measures and Therapeutic Outcomes Alvaro Morales, Brenda Johnston, Jeremy P.W. Heaton, Mark Lundie MoralesAlvaro Morales , JohnstonBrenda Johnston HeatonJeremy Heaton LundieMark View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65062-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints...
No AccessJournal of Urology1 Jun 1987Is Yohimbine Effective in the Treatment Organic Impotence? Results a Controlled Trial Alvaro Morales, Michael Condra, James A. Owen, David H. Surridge, Janet Fenemore, and Carol Harris MoralesAlvaro Morales , CondraMichael Condra OwenJames Owen SurridgeDavid Surridge FenemoreJanet Fenemore HarrisCarol View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)44436-3AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints...